Reporting owner · Q3 2026 · CIK 1451612

Booth Bruce: insider trades.

Booth Bruce reported 14 non-derivative transactions on 1 SEC ownership filings in Q3 2026: 0 open-market purchases and 14 sales ($8.3M), across 1 company.

Transactions
14
Purchases (P)
0
Sales (S)
14
Companies
1
Name as filed
Booth Bruce

Companies

CompanyRelationshipTransactions
Kymera Therapeutics, Inc. (KYMR)Director14

Transactions

14 non-derivative rows. Shares and prices as filed.
DateCompanyCodeSharesPriceOwned afterFiling
2026-06-29Kymera Therapeutics, Inc.S10,848$108.282,401,310Form 4/A
2026-06-29Kymera Therapeutics, Inc.S7,968$109.752,393,342Form 4/A
2026-06-29Kymera Therapeutics, Inc.S7,723$110.672,385,619Form 4/A
2026-06-29Kymera Therapeutics, Inc.S770$105.78471,497Form 4/A
2026-06-29Kymera Therapeutics, Inc.S2,133$106.63469,364Form 4/A
2026-06-29Kymera Therapeutics, Inc.S2,698$107.76466,666Form 4/A
2026-06-29Kymera Therapeutics, Inc.S1,498$108.28465,168Form 4/A
2026-06-29Kymera Therapeutics, Inc.S1,104$109.75464,064Form 4/A
2026-06-29Kymera Therapeutics, Inc.S1,078$110.67462,986Form 4/A
2026-06-29Kymera Therapeutics, Inc.S130$111.2462,856Form 4/A
2026-06-29Kymera Therapeutics, Inc.S19,419$107.762,412,158Form 4/A
2026-06-29Kymera Therapeutics, Inc.S14,798$106.632,431,577Form 4/A
2026-06-29Kymera Therapeutics, Inc.S5,549$105.782,446,375Form 4/A
2026-06-29Kymera Therapeutics, Inc.S934$111.22,384,685Form 4/A

Questions

What stock did Booth Bruce buy or sell?

Booth Bruce reported 14 non-derivative transactions on 1 SEC ownership filings in Q3 2026: 0 open-market purchases and 14 sales ($8.3M), across 1 company.

Is Booth Bruce the same person as other filers with this name?

This page covers SEC CIK 1451612 only. The SEC assigns each reporting owner a CIK, and people with the same name have different CIKs.

Source: SEC Insider Transactions Data Sets, Q3 2026. Reported as filed; we do not assess intent, performance or compliance. All filings for this CIK on SEC.gov.

Plain-text version for agents and LLMs: /insiders/booth-bruce-1451612.md

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.